We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · December 03, 2019

Liraglutide Reduced MACE in Patients With Type 2 Diabetes at High CV Risk

JAMA Cardiology


Additional Info

JAMA Cardiology
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial
JAMA Cardiol 2019 Nov 13;[EPub Ahead of Print], S Verma, SC Bain, JB Buse, T Idorn, S Rasmussen, DD Ørsted, MA Nauck

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading